ArticleHaematologica2010
Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study.
Article in Haematologica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01315925 (SEIFEM 2010), which is not on this map. Cited by 125 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SEIFEM 2010: Epidemiological Survey on Possible Pre-Hospital Risk Factors for Developing Invasive Fungal Infections in Patients Affected by Acute Myeloid Leukemia
Who cites it
125 citing papers in PubMed, 6 syntheses or guidelines pooled it, 307 citations in OpenAlex.
- Antifungal Stewardship in Invasive Fungal Infections, a Systematic Review.Advances in experimental medicine and biology · 2025Pooled it
- Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis.BMC infectious diseases · 2017Pooled it
- Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2014Pooled it
- Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Annals of hematology · 2014Guideline
- Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials.British journal of cancer · 2012Pooled it
- Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome.BMC infectious diseases · 2023Trial
- Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study.Annals of hematology · 2016Trial
- Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.Antimicrobial agents and chemotherapy · 2015Trial
- Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study.Cancer medicine · 2014Trial
- Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.Antimicrobial agents and chemotherapy · 2013Trial
- Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009.Haematologica · 2011Trial
- Disseminated Aspergillosis with Central Nervous System Involvement Among Patients with Hematologic Malignancies: A 30-Year Institutional Cohort of Clinical Features, Management, and Outcomes.Journal of fungi (Basel, Switzerland) · 2026Article
- Therapeutic Failure in Invasive Fungal Infections: Beyond Antifungal Resistance-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2026Review
- Hospital length of stay and cost associated with routine-care documentation of probable or suspected fungal infection among patients hospitalized with acute myeloid leukemia: a propensity score analysis.BMC infectious diseases · 2026Article
- Subtherapeutic posaconazole exposure during delayed-release tablet prophylaxis in high-risk patients with haematological malignancies: rationale for routine therapeutic drug monitoring.The Journal of antimicrobial chemotherapy · 2026Observational
- Immune interaction betweenFrontiers in cellular and infection microbiology · 2026Article
- Article
- Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics.Journal of food and drug analysis · 2025Review
- Treatment of Invasive Fungal Disease During Therapy for Acute Lymphoblastic Leukemia.Journal of medical cases · 2025Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 20 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to evaluate prognostic factors, treatments and outcome of invasive aspergillosis in patients with acute myeloid leukemia based on data collected in a registry. DESIGN AND
methodsThe registry, which was activated in 2004 and closed in 2007, collected data on patients with acute myeloid leukemia, admitted to 21 hematologic divisions in tertiary care centers or university hospitals in Italy, who developed proven or probable invasive aspergillosis.
resultsOne hundred and forty cases of invasive aspergillosis were collected, with most cases occurring during the period of post-induction aplasia, the highest risk phase in acute myeloid leukemia. The mortality rate attributable to invasive aspergillosis was 27%, confirming previous reports of a downward trend in this rate. Univariate and multivariate analyses revealed that the stage of acute myeloid leukemia and the duration of, and recovery from, neutropenia were independent prognostic factors. We analyzed outcomes after treatment with the three most frequently used drugs (liposomal amphotericin B, caspofungin, voriconazole). No differences emerged in survival at day 120 or in the overall response rate which was 71%, ranging from 61% with caspofungin to 84% with voriconazole.
conclusionsOur series confirms the downward trend in mortality rates reported in previous series, with all new drugs providing similar survival and response rates. Recovery from neutropenia and disease stage are crucial prognostic factors. Efficacious antifungal drugs bridge the period of maximum risk due to poor hematologic and immunological reconstitution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.